Last reviewed 2026-04-20 · How we verify

Mervometostat (PF-06821497) (mervometostat-pf-06821497)

Pfizer Inc. · Phase 1 active Quality 0/100

Mervometostat (PF-06821497) (generic name: mervometostat-pf-06821497) is a drug developed by Pfizer Inc.. It is currently in Phase 1 development.

At a glance

Generic name	mervometostat-pf-06821497
Sponsor	Pfizer Inc.
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Mervometostat (PF-06821497) CI brief — competitive landscape report
Mervometostat (PF-06821497) updates RSS · CI watch RSS
Pfizer Inc. portfolio CI

Frequently asked questions about Mervometostat (PF-06821497)

What is Mervometostat (PF-06821497)?

Mervometostat (PF-06821497) (mervometostat-pf-06821497) is a pharmaceutical drug developed by Pfizer Inc..

Who makes Mervometostat (PF-06821497)?

Mervometostat (PF-06821497) is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).

What is the generic name of Mervometostat (PF-06821497)?

mervometostat-pf-06821497 is the generic (nonproprietary) name of Mervometostat (PF-06821497).

What development phase is Mervometostat (PF-06821497) in?

Mervometostat (PF-06821497) is in Phase 1.

Manufacturer: Pfizer Inc. — full pipeline
Compare: Mervometostat (PF-06821497) vs similar drugs
Pricing: Mervometostat (PF-06821497) cost, discount & access